Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada
Sunshine Biopharma (NASDAQ:SBFM) has expanded its generic drug portfolio in Canada, launching nine new prescription drugs in 2024. This brings the company's total marketed drugs to 61. The new additions include Abiraterone, Clobetasol, Daptomycin, Dasatinib, Ertapenem, Hanzema®, Progesterone, Rivaroxaban, and Zoledronic Acid, addressing various health areas such as oncology, anti-inflammatory, antibacterial, dermatology, endocrinology, cardiovascular, and osteoporosis.
These drugs are currently sold under distribution agreements, differing from Nora Pharma's usual cross-licensing arrangements. The expansion aims to strengthen Sunshine Biopharma's presence in the $9.7 billion Canadian generic drug market and improve access to pharmacies. The company anticipates additional product launches in the near future.
Sunshine Biopharma (NASDAQ:SBFM) ha ampliato il suo portafoglio di farmaci generici in Canada, lanciando nove nuovi farmaci da prescrizione nel 2024. Questo porta il numero totale di farmaci commercializzati dall'azienda a 61. Le nuove aggiunte includono Abiraterone, Clobetasol, Daptomicina, Dasatinib, Ertapenem, Hanzema®, Progesterone, Rivaroxaban e Acido Zoledronico, che coprono diverse aree sanitarie come oncologia, anti-infiammatori, antibatterici, dermatologia, endocrinologia, cardiovascolare e osteoporosi.
Questi farmaci vengono attualmente venduti sotto accordi di distribuzione, a differenza dei consueti accordi di sublicenza di Nora Pharma. L'espansione mira a rafforzare la presenza di Sunshine Biopharma nel mercato canadese dei farmaci generici da 9,7 miliardi di dollari e migliorare l'accesso alle farmacie. L'azienda prevede lanci di prodotti aggiuntivi nel prossimo futuro.
Sunshine Biopharma (NASDAQ:SBFM) ha ampliado su portafolio de medicamentos genéricos en Canadá, lanzando nueve nuevos medicamentos recetados en 2024. Esto eleva el total de medicamentos comercializados por la empresa a 61. Las nuevas adiciones incluyen Abiraterona, Clobetasol, Daptomicina, Dasatinib, Ertapenem, Hanzema®, Progesterona, Rivaroxabán y Ácido Zoledrónico, abarcando diversas áreas de salud como oncología, antiinflamatorios, antibacterianos, dermatología, endocrinología, cardiovascular y osteoporosis.
Estos medicamentos se venden actualmente bajo acuerdos de distribución, lo que difiere de los acuerdos de sublicencia habituales de Nora Pharma. La expansión tiene como objetivo fortalecer la presencia de Sunshine Biopharma en el mercado canadiense de medicamentos genéricos de 9.7 mil millones de dólares y mejorar el acceso a las farmacias. La compañía anticipa lanzamientos de productos adicionales en un futuro cercano.
썬샤인 바이오파르마 (NASDAQ:SBFM)는 2024년에 캐나다에서 9개 새로운 처방약을 출시하며 제네릭 약물 포트폴리오를 확장했습니다. 이를 통해 회사의 총 판매 약품 수는 61개가 됩니다. 새로운 추가 약물에는 아비라테론, 클로베타솔, 다포마이신, 다사티닙, 에르타페넴, 한세마®, 프로게스테론, 리바록사반, 졸레드론산이 포함되어 있으며, 종양학, 항염증제, 항균제, 피부과, 내분비학, 심혈관 및 골다공증 등의 다양한 건강 영역을 다룹니다.
이 약물들은 현재 노라 제약의 통상적인 크로스 라이센스 계약과는 다른 유통 계약하에 판매되고 있습니다. 이번 확장은 썬샤인 바이오파르마의 97억 달러 규모의 캐나다 제네릭 약물 시장에서의 입지를 강화하고 약국에 대한 접근성을 개선하는 것을 목표로 하고 있습니다. 회사는 가까운 미래에 추가 제품 출시를 예상하고 있습니다.
Sunshine Biopharma (NASDAQ:SBFM) a élargi son portefeuille de médicaments génériques au Canada, lançant neuf nouveaux médicaments sur ordonnance en 2024. Cela porte le total des médicaments commercialisés par l'entreprise à 61. Les nouveaux ajouts comprennent Abiraterone, Clobétasol, Daptomycine, Dasatinib, Ertapénem, Hanzema®, Progestérone, Rivaroxaban et Acide Zoledronique, couvrant divers domaines de santé tels que l'oncologie, les anti-inflammatoires, les antibactériens, la dermatologie, l'endocrinologie, les maladies cardiovasculaires et l'ostéoporose.
Ces médicaments sont actuellement vendus sous des accords de distribution, différemment des accords de sous-licence habituels de Nora Pharma. L'expansion vise à renforcer la présence de Sunshine Biopharma sur le marché canadien des médicaments génériques de 9,7 milliards de dollars et à améliorer l'accès aux pharmacies. L'entreprise prévoit des lancements de produits supplémentaires dans un futur proche.
Sunshine Biopharma (NASDAQ:SBFM) hat sein Portfolio an Generika in Kanada erweitert und 2024 neun neue verschreibungspflichtige Medikamente auf den Markt gebracht. Dadurch erhöht sich die Gesamtanzahl der vermarkteten Medikamente des Unternehmens auf 61. Zu den neuen Ergänzungen gehören Abirateron, Clobetasol, Daptomycin, Dasatinib, Ertapenem, Hanzema®, Progesteron, Rivaroxaban und Zoledronsäure, die verschiedene Gesundheitsbereiche wie Onkologie, entzündungshemmende Mittel, Antibakterien, Dermatologie, Endokrinologie, Herz-Kreislauf-Erkrankungen und Osteoporose abdecken.
Diese Medikamente werden derzeit unter Vertriebsvereinbarungen verkauft, was sich von den üblichen Lizenzverträgen von Nora Pharma unterscheidet. Die Expansion zielt darauf ab, die Präsenz von Sunshine Biopharma im 9,7 Milliarden US-Dollar schweren kanadischen Generikamarkt zu stärken und den Zugang zu Apotheken zu verbessern. Das Unternehmen erwartet in naher Zukunft weitere Produkteinführungen.
- Launched 9 new generic prescription drugs in 2024
- Total number of marketed drugs increased to 61
- Expanded presence in the $9.7 billion Canadian generic drug market
- Diversified portfolio addressing various health areas
- None.
Insights
The launch of nine new generic drugs by Sunshine Biopharma is a significant expansion of their product portfolio, now totaling 61 drugs in the Canadian market. This diversification across multiple therapeutic areas, including oncology, cardiovascular and antibacterials, strengthens their market position. However, the distribution agreement model for these new drugs, differing from their usual cross-licensing arrangements, may impact profit margins. The company's strategy to become a go-to supplier for everyday medicines could lead to increased market share in the
Sunshine Biopharma's expansion into new therapeutic areas is a strategic move to capture a larger slice of the Canadian generic drug market. The diverse range of new drugs, including treatments for critical conditions like cancer and cardiovascular diseases, positions the company to meet varied healthcare needs. This could lead to increased pharmacy penetration and potentially higher sales volumes. However, the generic drug market is highly competitive, with price pressures being a constant challenge. The success of this expansion will largely depend on Sunshine Biopharma's ability to efficiently manage production costs, navigate regulatory landscapes and effectively market these new offerings. Investors should watch for future quarterly reports to gauge the revenue impact of these new launches and any changes in the company's market share.
While the expansion of Sunshine Biopharma's product line is promising, investors should focus on the financial implications. The company's shift to distribution agreements for these new drugs, as opposed to their usual cross-licensing model, may affect profit margins. It's important to monitor upcoming financial reports for changes in revenue growth rates and gross margins. The Canadian generic drug market, valued at
FORT LAUDERDALE, FL / ACCESSWIRE / August 26, 2024 / Sunshine Biopharma, Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that it has launched nine (9) new generic prescription drugs year-to-date. These launches bring the total number of drugs that the Company has on the market in Canada to sixty-one (61). The Company's marketing and sales efforts are carried out by Nora Pharma Inc. (Nora Pharma), a wholly owned subsidiary of the Company.
The new generic prescription drugs launched include Abiraterone, Clobetasol, Daptomycin, Dasatinib, Ertapenem, Hanzema®, Progesterone, Rivaroxaban, and Zoledronic Acid. These new drugs address various human health areas including oncology, anti-inflammatory, antibacterial, dermatology, endocrinology, cardiovascular, and osteoporosis.
These nine (9) drugs were included in the list of "Products on the Market" provided in our recently filed 10-Q/A for the quarter ended June 30, 2024. They are currently being sold under distribution agreements instead of Nora Pharma's commonly used cross-licensing arrangements. The current marketing arrangement for these drugs may change in the future.
"The addition of these new products to our existing portfolio will strengthen our presence in the Canadian
About Sunshine Biopharma, Inc.
Sunshine Biopharma currently has 61 generic prescription drugs on the market in Canada and 32 additional drugs scheduled to be launched in the remainder of 2024 and in 2025. Among the new drugs to be launched in 2024 is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy.
In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: www.sunshinebiopharma.com.
All registered trademarks are the property of their respective owners.
Safe Harbor Forward-Looking Statements
This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma, Inc. (the "Company") that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
For Additional Information:
Sunshine Biopharma Contact:
Camille Sebaaly, CFO
Direct Line: 514-814-0464
camille.sebaaly@sunshinebiopharma.com
SOURCE: Sunshine Biopharma, Inc.
View the original press release on accesswire.com
FAQ
How many new generic prescription drugs has Sunshine Biopharma (SBFM) launched in 2024?
What is the total number of drugs Sunshine Biopharma (SBFM) now markets in Canada?
What are some of the new generic drugs launched by Sunshine Biopharma (SBFM) in 2024?
What is the size of the Canadian generic drug market that Sunshine Biopharma (SBFM) is targeting?
